[Pubmed] Efficacy and safety of efgartigimod in the treatment of impending myasthenic crisis
Posté : 30 mars 2026 12:00
Front Immunol. 2026 Mar 12;17:1760953. doi: 10.3389/fimmu.2026.1760953. eCollection 2026.
ABSTRACT
OBJECTIVE: To compare the short-term efficacy and safety of efgartigimod versus intravenous immunoglobulin (IVIg) in patients with impending myasthenic crisis (IMC).
METHODS: This single-center, randomized, open-label, prospective comparative cohort study included 38 acetylcholine receptor antibody-positive (AChR-Ab+) patients with IMC, which was defined as rapid progression of bulbar or respiratory symptoms within ≤2 weeks, meeting at least one of the following criteria:Myasthenia Gravis Foundation of America (MGFA) grade IVb, a Quantitative Myasthenia Gravis (QMG) bulbar subscore of 3, a respiratory subscore of 2, or a combined bulbar-respiratory subscore ≥4. The participants were included and categorized into either the efgartigimod group (n=21; 10 mg/kg weekly for 4 weeks) or the IVIg group (n=17; 400 mg/kg/day for 5 days). The primary endpoints were the rate of IMC remission within one month (defined as a QMG score
Source: https://pubmed.ncbi.nlm.nih.gov/4190965 ... t6+133c1fe